HDAC9 promotes atherosclerosis by suppressing CYP7A1 and impairing hepatic cholesterol excretion
Clinical Science · 12.08.2026 · 140 (8) · 1709-1723
DOI: 10.1042/cs20260062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Science, online erschienen am 16.07.2026. Verfasst von Rongzhan Lin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Nanfang Hospital, Southern Medical University…. Hauptthemen laut MEDLINE: Cholesterol 7-alpha-Hydroxylase, Histone Deacetylases, Atherosclerosis, Liver. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 2.0). Gefördert von: MOST | National Key Research and Development Program of China (NKPs), MOST | National Natural Science Foundation of China | (NSFC)[], MOST | National Natural Science Foundation of China (NSFC).
Abstract (Originalsprache)
Histone deacetylase 9 (HDAC9) exacerbates atherosclerosis through inflammatory pathways, yet its specific role in cholesterol metabolism remains to be fully elucidated. Here, we investigated whether HDAC9 promotes atherosclerosis by impairing hepatic cholesterol excretion via bile acid synthesis. Using ApoE−/− and ApoE−/−PSRC1−/− mice fed a high-fat diet (HFD), we observed that PSRC1 deficiency or HFD feeding up-regulated hepatic HDAC9 expression, concomitant with suppression of the rate-limiting bile acid enzyme CYP7A1. Pharmacological inhibition of HDAC9 (TMP195) or liver-targeted AAV8-shHdac9 knockdown restored CYP7A1 expression, reduced plasma LDL-C, and attenuated aortic plaque burden in HFD-fed ApoE−/− mice. In vitro assays in Hep1-6 and HepG2 hepatocytes confirmed that Hdac9 knockdown attenuated free fatty acid-induced cholesterol accumulation, while overexpression exacerbated it. Mechanistically, HDAC9 transcriptionally represses Cyp7a1, as the cholesterol-lowering effect of Hdac9 knockdown was abolished by concomitant Cyp7a1 silencing. Collectively, our findings indicate that HDAC9 promotes atherosclerosis by transcriptionally repressing Cyp7a1 and impairing bile acid synthesis, independent of its inflammatory roles. These results highlight hepatic HDAC9 as a promising therapeutic target for hypercholesterolemia and advocate for the development of liver-directed HDAC9 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Cardiovascular Center, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology(Nanhai District People's Hospital of Foshan), Foshan, 528200,Guangdong, China.
- Cancer Center, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China.
ORCID-Profile: Yulin Liao
Förderung
- MOST | National Key Research and Development Program of China (NKPs)
- MOST | National Natural Science Foundation of China | (NSFC)[]
- MOST | National Natural Science Foundation of China (NSFC)
- MOST | National Natural Science Foundation of China 大多数 | 中国国家自然科学基金会 (NSFC)[中国]
Zitieren
APA
Lin, R., Li, M., Liu, J., He, M., Li, Z., Jin, J., Zhang, R., Zheng, C., Chen, L., Shen, M., Lin, H., Liao, W., Bin, J., Wang, Q., Guo, Z., & Liao, Y. (2026). HDAC9 promotes atherosclerosis by suppressing CYP7A1 and impairing hepatic cholesterol excretion. Clinical Science, 140(8), 1709-1723. https://doi.org/10.1042/cs20260062
Vancouver
Lin R, Li M, Liu J, He M, Li Z, Jin J, et al. HDAC9 promotes atherosclerosis by suppressing CYP7A1 and impairing hepatic cholesterol excretion. Clinical Science. 2026;140(8):1709-1723. doi:10.1042/cs20260062
BibTeX
@article{Lin2026,
author = {Lin, Rongzhan and Li, Mingjue and Liu, Jichen and He, Mingyuan and Li, Zhihong and Jin, Jiarui and Zhang, Rui and Zheng, Cankun and Chen, Lu and Shen, Mengjia and Lin, Hairuo and Liao, Wangjun and Bin, Jianping and Wang, Qiancheng and Guo, Zhigang and Liao, Yulin},
title = {HDAC9 promotes atherosclerosis by suppressing CYP7A1 and impairing hepatic cholesterol excretion},
journal = {Clinical Science},
year = {2026},
volume = {140},
number = {8},
pages = {1709--1723},
doi = {10.1042/cs20260062}
}
EUVIMED